Why is Trump simultaneously murdering people on small boats whose identities we don’t really know (but he insists they’re drug smugglers) while also freeing people we *know* are guilty of drug crimes?
REDHART2 is a simple study - hospitalized for HFrEF --> CPET within 2 weeks of discharge, treatment with anakinra (or placebo, 2:1) for 6 months, CPET repeated at 6, 12, and 24 weeks. Four visits in 6 months all at VCU. Reach out to me or @bvantassell with questions.
Journal publication is a multi-billion industry… and this article estimates that academics donate at least $1.5b annually in labor to support the current enterprise. Write papers, donate reviews, often pay for publication. What a model. https://t.co/Twf4s8SULQ HT @atulbutte
We received feedback on our latest set of faculty surveys but don’t believe it is representative of the faculty because of what we have been told in private meetings. Thanks for participating!
Are the NLRP3 inflammasome and interleukin 1-beta potentially novel therapeutic targets for the treatment of #pericarditis?
Find out in this new issue of #JACCBTS: https://t.co/1tjZLAHVoj #CardioImmunology
STAT request: 2021 MeRIT Scholarship Applications due today February 8 at 8pm EST. Receive $3,000 to develop expertise in investigator-initiated research over a 2-year program. Contact [email protected] (@lfbpharmd ) for questions
Proud to have been part of RHAPSODY at @VCUHealthHeart @VCU_CCTR
Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis | NEJM https://t.co/hGgrroUSoC
After sitting in study section last week reviewing proposals for K-series career development awards, thought I'd list my top 5 reasons why such proposals fail. (Not linked to any one submission.)
Junior scientists who might be interested in applying - avoid these pitfalls!!
Remote, algorithm-driven, navigator-administered medication optimization enhanced utilization and dose titration of neurohormonal antagonists versus usual care in HFrEF. This approach may represent a novel strategy to address underutilization of GDMT https://t.co/PvinA0t6nq
Medicaid Expansion & Antihyperglycemic Therapies in @ADA_Journals by @adsumarsono, @sara_rm84, & colleagues.
Low-income adults carry a disproportionate burden of CV disease. Improving insurance coverage represents a key determinant of therapeutic access.
https://t.co/dTHSgrUach
I am excited to share our editorial just published on @JACCJournals where we discuss the role of nutrition in the management of heart failure, beyond dietary sodium restriction. @vcukhs@VCUCHS@VCUnews https://t.co/OyDRwrVaAZ
COPS trial: in a small RCT, colchicine did not improve a composite of death or CV outcomes at 12 mos post ACS. Small # of events. Adverse non-CV mortality signal (5 vs 0 favoring placebo) 🤷🏽♂️ @UTSWIMchief@UTSWCardfellow https://t.co/jFMDXx8oO6
VCUART3 study showed promising benefits of IL-1 blockade with anakinra in STEMI. https://t.co/0knDpdxOuS
Looking for other centers in the USA for a phase II trial with a novel IL-1 blocker (contact me [email protected] if interested)